What is William Blair’s Estimate for IONS Q1 Earnings?

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) – Investment analysts at William Blair issued their Q1 2026 earnings per share (EPS) estimates for shares of Ionis Pharmaceuticals in a research note issued on Wednesday, February 19th. William Blair analyst M. Minter anticipates that the company will post earnings of ($1.17) per share for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Ionis Pharmaceuticals’ current full-year earnings is ($3.50) per share. William Blair also issued estimates for Ionis Pharmaceuticals’ Q2 2026 earnings at ($1.07) EPS, Q3 2026 earnings at ($0.89) EPS and Q4 2026 earnings at ($0.85) EPS.

Ionis Pharmaceuticals (NASDAQ:IONS) last issued its earnings results on Wednesday, February 19th. The company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($1.12) by $0.46. The firm had revenue of $227.00 million during the quarter, compared to the consensus estimate of $140.97 million. Ionis Pharmaceuticals had a negative net margin of 64.25% and a negative return on equity of 100.05%. The business’s quarterly revenue was down 30.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.12 earnings per share.

A number of other research analysts have also recently issued reports on the company. Royal Bank of Canada reissued an “outperform” rating and issued a $70.00 target price on shares of Ionis Pharmaceuticals in a research note on Thursday, February 20th. StockNews.com cut Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, November 12th. Needham & Company LLC reissued a “buy” rating and set a $60.00 target price on shares of Ionis Pharmaceuticals in a research note on Thursday, February 20th. BMO Capital Markets cut their price target on shares of Ionis Pharmaceuticals from $60.00 to $45.00 and set a “market perform” rating on the stock in a research note on Thursday, February 20th. Finally, Citigroup lowered their price objective on shares of Ionis Pharmaceuticals from $67.00 to $64.00 and set a “buy” rating for the company in a research report on Thursday, February 20th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $60.00.

Ionis Pharmaceuticals Price Performance

Shares of IONS stock opened at $31.85 on Monday. The company has a quick ratio of 8.82, a current ratio of 8.47 and a debt-to-equity ratio of 2.12. Ionis Pharmaceuticals has a 12-month low of $30.23 and a 12-month high of $52.34. The firm has a fifty day moving average of $33.41 and a 200-day moving average of $38.03. The firm has a market capitalization of $5.06 billion, a price-to-earnings ratio of -10.48 and a beta of 0.34.

Insider Buying and Selling

In other Ionis Pharmaceuticals news, EVP Patrick R. O’neil sold 1,207 shares of the stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $32.35, for a total value of $39,046.45. Following the completion of the sale, the executive vice president now owns 56,245 shares in the company, valued at $1,819,525.75. This trade represents a 2.10 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Michael R. Hayden acquired 5,000 shares of the firm’s stock in a transaction dated Monday, December 23rd. The stock was purchased at an average cost of $36.22 per share, with a total value of $181,100.00. Following the transaction, the director now owns 35,219 shares in the company, valued at approximately $1,275,632.18. This trade represents a 16.55 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders have sold 111,816 shares of company stock worth $3,603,914. Corporate insiders own 2.71% of the company’s stock.

Institutional Trading of Ionis Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Signaturefd LLC increased its holdings in shares of Ionis Pharmaceuticals by 160.0% during the 4th quarter. Signaturefd LLC now owns 949 shares of the company’s stock worth $33,000 after acquiring an additional 584 shares during the last quarter. Huntington National Bank increased its holdings in shares of Ionis Pharmaceuticals by 193.5% in the fourth quarter. Huntington National Bank now owns 951 shares of the company’s stock valued at $33,000 after purchasing an additional 627 shares during the last quarter. Lindbrook Capital LLC increased its holdings in shares of Ionis Pharmaceuticals by 183.8% in the fourth quarter. Lindbrook Capital LLC now owns 1,036 shares of the company’s stock valued at $36,000 after purchasing an additional 671 shares during the last quarter. Capital Performance Advisors LLP acquired a new stake in shares of Ionis Pharmaceuticals during the 3rd quarter worth about $40,000. Finally, Prospera Private Wealth LLC bought a new stake in shares of Ionis Pharmaceuticals during the 3rd quarter worth about $42,000. 93.86% of the stock is owned by institutional investors and hedge funds.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.